Author Archives: Alice Melão

I-Mab Expands its Ongoing Myeloma Clinical Trials of MOR202 to China

I-Mab Biopharma is expanding to mainland China its ongoing clinical studies assessing MorphoSys‘ investigational antibody therapy MOR202 (TJ202) as treatment for people with multiple myeloma, the company announced. The decision comes after an Investigational New Drug clearance issued by China’s National Medical Products Administration (NMPA). The…

Early Data Show Positive Activity of Iberdomide Against Heavily Treated MM

Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and controlled disease in nearly 90% of multiple myeloma patients who had failed multiple prior treatments. The preliminary findings were discussed in an oral presentation, “…

FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase 3 trial (NCT02755597). This means that all ongoing clinical trials assessing AbbVie‘s venetoclax in multiple myeloma can no longer…